Simplify Asset Management Inc. Acquires 7,296 Shares of Gilead Sciences, Inc. $GILD

30 Dec 2025, 08:30 by Amy Steele · The Cerbat Gem

Simplify Asset Management Inc. boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 13.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 60,186 shares of the biopharmaceutical company’s stock after purchasing an additional 7,296 shares during the quarter. Gilead Sciences comprises approximately 0.1% of Simplify Asset Management Inc.’s holdings, making the stock its 24th largest position. Simplify Asset Management Inc.’s holdings in Gilead Sciences were worth $6,681,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Gilead Sciences by 1.6% in the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after acquiring an additional 1,893,401 shares during the period. Geode Capital Management LLC raised its stake in Gilead Sciences by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after purchasing an additional 727,515 shares during the last quarter. Norges Bank bought a new stake in Gilead Sciences in the 2nd quarter valued at $2,150,268,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Gilead Sciences by 12.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock worth $1,541,302,000 after purchasing an additional 1,520,809 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after purchasing an additional 3,394,330 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.2%

Shares of GILD opened at $124.91 on Tuesday. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The stock has a 50 day simple moving average of $122.99 and a 200-day simple moving average of $116.80. The stock has a market cap of $154.97 billion, a PE ratio of 19.37, a PEG ratio of 0.69 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter last year, the company earned $2.02 EPS. Gilead Sciences’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on GILD shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a research note on Friday, October 31st. Wolfe Research reaffirmed an “outperform” rating and issued a $150.00 price target on shares of Gilead Sciences in a report on Monday, December 15th. Daiwa Capital Markets lifted their price objective on Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Wall Street Zen cut Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 20th. Finally, Wells Fargo & Company raised their target price on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $131.68.

Check Out Our Latest Stock Analysis on GILD

Insider Activity

In other Gilead Sciences news, EVP Deborah H. Telman sold 53,646 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the transaction, the executive vice president directly owned 43,676 shares in the company, valued at $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the sale, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. The trade was a 1.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 126,257 shares of company stock worth $15,606,892 over the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.